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Background: It is now recognized that the neuro-vascular unit (NVU) plays a key role in several neurological
diseases including epilepsy, stroke, Alzheimer’s disease, multiple sclerosis and the development of gliomas. Most of
these disorders are associated with NVU dysfunction, due to overexpression of inflammatory factors such as
vascular endothelial growth factor (VEGF). Various in vitro models have been developed previously to study the
micro-environment of the blood–brain barrier (BBB). However none of these in vitro models contained a complete
complement of NVU cells, nor maintained their interactions, thus minimizing the influence of the surrounding
tissue on the BBB development and function. The organotypic hippocampal culture (OHC) is an integrative in vitro
model that allows repeated manipulations over time to further understand the development of cell circuits or the
mechanisms of brain diseases.
Methods/design: OHCs were cultured from hippocampi of 6–7 day-old Sprague Dawley rats. After 2 weeks in
culture, seizures were induced by application of kainate or bicuculline into culture medium. The regulation of BBB
integrity under physiological and pathological conditions was evaluated by immunostaining of the main tight
junction (TJ) proteins and of the basal membrane of microvessels. To mimic or prevent BBB disassembly, we used
diverse pro- or anti-angiogenic treatments.
Discussion: This study demonstrates that NVU regulation can be investigated using OHCs. We observed in this
model system an increase in vascularization and a down-regulation of TJ proteins, similar to the vascular changes
described in a chronic focus of epileptic patients, and in rodent models of epilepsy or inflammation. We observed
that Zonula occludens-1 (ZO-1) protein disappeared after seizures associated with neuronal damage. In these
conditions, the angiopoeitin-1 system was down-regulated, and the application of r-angiopoeitin-1 allowed TJ
re-assembly. This article demonstrates that organotypic culture is a useful model to decipher the links between
epileptic activity and vascular damage, and also to investigate NVU regulation in diverse neurological disorders.
Keywords: Neurovascular unit (NVU), Blood–brain barrier (BBB), Organotypic brain slices, EpilepsyBackground
Homeostatic maintenance is essential for proper cerebral
function. The blood vessel- and non-vascular cells (neu-
rons and glial cells) in the brain form the neurovascular
unit (NVU) [1]. The NVU plays an important role in brain
maintenance via cellular interactions between microvessels
and parenchyma. Under physiological conditions, the NVU
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distribution, and reproduction in any mediumtoxin elimination and brain protection. Adherens junctions
(AJs) and tight junctions (TJs) reduce the paracellular flux
across brain endothelium, whereas specific transporters
and receptors carry glucose, amino-acids, nucleosides, or-
ganic anions, large amino-acids, transferrin, lipo-proteins
and drugs into the brain. Conversely, pathological stimuli
that increase blood–brain barrier (BBB) permeability per-
turb brain homeostasis. The leakage of ions, water, and
serum proteins into the parenchyma modifies oncotic pres-
sure and ionic concentrations, while leukocyte extravasa-
tion triggers immune and inflammatory responses. This
imbalance leads to abnormal neuronal activity or toxicity.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cerebral cortex these features induce seizures. In several
CNS structures, increased BBB permeability participates in
or worsens neurological disorders like Alzheimer’s disease,
multiple sclerosis or chronic epilepsy [2-5].
Modeling the NVU in vitro has furthered the under-
standing of selective mechanisms which regulate perme-
ability, toxin elimination, nutrient supply, brain protection
and homeostasis regulation. Several in vitro cell-based
BBB models have previously been developed but were un-
able to fully recapitulate all known features of the BBB
[6,7]. Despite the conservation of endothelial cell proper-
ties ex vivo, their isolation from multicellular blood vessels
is methodologically difficult [8]. The endothelial cell
monolayer is one of the most commonly used in vitro
models; however, it only represents a simplified view of
the BBB. This simplification reduces the interactions with
other cell types, which are essential for BBB maintenance
[9,10]. The co-culture of astrocytes and endothelial cells is
the most validated cell-based BBB model. This model con-
tains TJs, transporters, ionic channels and high tran-
sendothelial electrical resistance (TEER) necessary for a
suitable model. However the absence of other cell types
such as pericytes is a limitation in dynamic studies of the
NVU, including vasomodulation [11]. To counteract the
lack of pericytes, the tri-culture has been developed using
endothelial cells, pericyte and astrocytes cell lines. In this
system, all cell types are necessary for the adequate
localization of TJs and transporter functions [12]. This
model can be modified depending on the research objec-
tives, using leukocytes or neurons as the third cell type
[13,14]. The tri-culture is currently one of the most repre-
sentative in vitro models to study BBB regulation in
humans [15].
Clearly, BBB models should contain most or all cellu-
lar and molecular players of the NVU and take into ac-
count the different environmental factors. Thirty years
ago, Gähwiler et al. described an integrative model to
study interactions between cell types in brain slices
maintained in culture [16]. This model was simplified by
growing organotypic brain slices on a membrane surface
[17]. These slices maintain all cell types and their inter-
actions for 2 weeks and were mainly used to study the
activity of neural cells under diverse physiologic and
pathologic conditions [18,19].
In 2003, it was shown for the first time that, despite
the absence of blood flow in organotypic cortical slices,
microvessels were present and able to respond to angio-
genic stimuli like acidosis or hyperthermia [20]. Further-
more, microvessels preserved within organotypic slices
respond to experimental seizures. We have used this
in vitro model to study the effects of seizure-like activity
on the NVU. We chose slices of rat hippocampus, since
the corresponding structure in the human brain isinvolved in temporal lobe epilepsy (TLE). We found that
kainate-induced epileptiform activities induced vascular
changes in organotypic slices including angiogenesis and
BBB alteration, similar to those reported in human in-
tractable TLE and in vivo models [21,22].Methods/ design
Organotypic brain slices
Organotypic hippocampal slices (OHCs) were prepared
and cultured according to Stoppini et al. [17]. The brains
of 6–7 day-old Sprague Dawley rats were removed after
cold anesthesia and hippocampi were rapidly dissected
under aseptic conditions in a dissection medium contain-
ing 50% HBSS, 50% Opti-MEM, penicillin 25 units/ml,
streptomycin 25 μg/ml (Life technologies, Grand Island,
NY, USA). Then transverse sections (400 μm) were
obtained using a tissue chopper. Ten slices were placed on
a 30 mm porous membrane (Millipore, Billerica MA,
USA) and kept in 100 mm diameter Petri dishes filled with
5 ml of culture medium composed of 25% heat-inactivated
horse serum, 25% HBSS, 50% Opti-MEM, penicillin 25
units/ml, streptomycin 25 μg/ml (Life technologies). Cul-
tures were maintained in a humidified incubator at 35°C
and 5% CO2. One week later, cultures were transferred in
defined medium composed of 25% B27 supplemented neu-
robasal medium, 25% HBSS, 50% Opti-MEM, penicillin 25
units/ml, streptomycin 25 μg/ml (Life technologies). All
animal procedures were conducted in accordance with the
European Communities Council Directive of November
24, 1986 (86/6 09/EEC), and approved by the French Min-
istry of Agriculture (Authorization No. 34178, ML-N).Induction of “in vitro seizure”
After 2 weeks, membranes were transferred to 6-well
plates, each well filled with 1 ml defined culture medium.
To induce seizures, slices were treated with 25 μM kainate
(Sigma-Aldrich, Saint-Louis, MO, USA) for 1 h or with
10 μM of bicuculline (Sigma-Aldrich) for 10 min. Control
slices received no treatment. Slices were then transferred in
a bicuculline-free or kainate free-defined culture medium
during the recovery period (2, 12 and 24 h).Treatments
Recombinant proteins
The rat recombinant vascular endothelial growth factor
(rrVEGF, R&D systems, Minneapolis, MN, USA) was
added into culture medium for 24 h at 2 ng/ml. The
rhAngiopoeitin-1 (rhAng-1, R&D systems) was added 4
h after seizure induction for 24 h at 400 ng/ml. LPS (100
ng/ml, Sigma-Aldrich) was added to the culture medium
for 24 h.
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Immunostaining Slices were fixed in 4% PFA for 30
min and stored at 4°C in PBS containing 0.1% NaNO3.
To evaluate vascular density and zonula occludens-1
(ZO-1) expression, immunohistochemistry was carried
out on free-floating whole slices. After pre-incubation
in a PBS solution containing 10% goat serum and 0.1%
Triton for 2 h at room temperature, slices were
incubated for 48 h at 4°C with mouse or rabbit
anti-laminin (Chemicon, Temecula CA, USA, 2E8, 1/
3000 or Sigma-Aldrich, L9393 1/4000, rabbit anti-ZO-
1 (Zymed, San Fransisco, CA, USA, 61–7300 1/200),
Goat anti-VEGF (Santa-Cruz, Santa Cruz, CA, USA,
Sc-1836, 1/200), rabbit anti-VEGFR-2 (Santa-Cruz, sc-
504, 1/200), mouse or rabbit anti-GFAP (Dako,
Glostrup, Denmark, 6F2, 1/1000) and mouse anti-
neuN (Chemicon, MAB377,1/500). After 3 washes in
PBS 1X, slices were incubated for 2 h at room
temperature with secondary fluorophore-coupled anti-
bodies against goat, mouse or rabbit. After 3 washes of
10 min in PBS 1X slices were mounted with Mowiol.
For vascular density, sections were observed with a
Leitz DMRB microscope (Leica, Wetzlar, Germany)
equipped for fluorescent microscopy. Images were
digitized by a 1392 × 1040 resolution cooled CCD cam-
era (Cool Snap, Princeton Instrument, Trenton, NJ,
USA) on a computer with Cool Snap software and
transferred to Adobe Photoshop Elements (version 4)
for image processing. For ZO-1, VEGF and VEGFR-2
immunostaining staining sections were observed using
a confocal microscope (Zeiss 510 Meta, Göttingen,
Germany) equipped with an x63 objective (oil, numeric
opening 1.4). We used an argon laser (excitation 488,
emission 505–530 nm) for alexa 488, a helium laser (exci-
tation 543, emission 585–615 nm) for Texas red and a
krypton-argon laser (excitation 647 nm, emission 660-700
nm) for alexa 647. Images were collected sequentially to
avoid cross-contamination between fluorochromes. A
series of 15 optical sections was projected onto a single
image plane and scanned at 1024 × 1024 pixel resolution.
Quantification of vascular density
We used the point-counting method to quantify and com-
pare the vascular density under different conditions [23].
This method has been already validated in human tissue,
in vivo and in organotypic cultures [20-22]. It takes into
account the number, size and tortuosity of vessels to
characterize pathological angiogenesis. Briefly, a 5 × 5 grid
was superposed onto the digitized image and the number
of labeled vessels crossing the grid lines was counted. The
score was expressed in arbitrary units of vascular density
for a 1 mm2 area. Statistical analysis was performed: one-
way analysis of variance (ANOVA) followed by Fisher test
for OHCs (p<0.05 is significant).Quantification of branching
To evaluate the branching after each treatment, we
selected magnifications of 0.5 mm2 areas in the two main
hippocampal fields: CA1 and CA3. Vessel branch points
resulting from microvascular sprouting [24], were counted
manually and results were expressed as a percent of con-
trols. Statistical analysis was performed by one-way ana-
lysis of variance (ANOVA) followed by Fisher test for
OHCs (p<0.05 is significant).
Protein expression and activation
Proteins were prepared according to our previous publi-
cation [21]. Protein samples (40 μg) boiled in Laemmli
buffer containing 2-β-mercaptoethanol were loaded onto a
NupageNovex 4-12% Bis-Tris Midi gel (Life Technologies),
separated electrophoretically and transferred to polyvinyl-
difluoridine membranes (Hybond-C-extra, Amersham
Biosciences, UK). Membranes were incubated overnight at
4°C with primary antibodies raised against VEGF (Santa
Cruz, Sc-1836 1/200), VEGFR-2 (Abcam, Cambridge, MA,
USA, Ab2349 1/1000), VEGFR-2P (Y1054 & Y1059)
(Abcam, Ab5473 1/1000), ZO-1 (Zymed, 61–7300 1/800),
claudin-5 (Life Technologies, 34–1600, 1/400), occludin
(Life Technologies, 71–1500, 1/500), or actin (LabVision,
Fremont, CA, USA, ACTN05 1/1000), then with HRP sec-
ondary antibodies against rabbit, goat or mouse IgG for
1 h at RT. Bands were visualised by chemoluminescence
detection (Western Lightening, Perkin Elmer, MA, USA).
Western blots were analyzed by densitometry using Photo-
shop and ImageJ and normalized with actin. Statistical ana-
lysis was performed by Kruskall-Wallis test, p<0.05 is
significant.
Cytokine array
The profile of cytokines released into the culture medium
was analyzed by proteome profiler using rat cytokine array
(R&D Systems, Minneapolis, MN, USA, # ARY008) accord-
ing to the manufacturer’s protocol. Results were analyzed
by densitometry using ImageJ. For heatmap analysis, a dif-
ference between optical density of control slices and treat-
ment conditions was calculated. Then the heatmap was
generated using the MeV software (Boston, MA, USA).
Results
Organotypic cultures: a tool to decipher the mechanisms
of BBB failure in epileptic disease
Since empty vessels respond to angiogenic factors, we
studied the vascular remodelling after epileptic seizures
using OHCs [20,25,26]. Previously, we observed the
presence of angiogenesis and BBB permeability in phar-
macoresistant temporal lobe epilepsies [22]. To deter-
mine if vascular remodeling was induced by seizures per
se, or by cell damage or inflammation associated with se-
vere seizures, we evaluated the vascular density in the
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by bicuculline; 2) inflammation induced by LPS; 3) sei-
zures with neuronal death and inflammation induced by
kainate.
To evaluate pathological angiogenesis, we measured vas-
cular density and branching (Figure 1A). As a positive
control, we also evaluated OHCs treated with VEGF. For
the “point-counting” method, the number of “crossings”
was counted and normalized to slice surface area in mm2.
The “branch point” was evaluated after magnifying theFigure 1 Blood vessel responses to seizure-like activity in organotypi
during the angiogenic process. Angiogenesis is the formation of a new blo
guidance and the creation of new blood vessels. (B) For the point-counting
basal membrane (green). A grid is placed on the picture and the number o
vascular density evaluation takes into account the length, tortuosity and di
is calculated per mm2. Scale Bar: 400 μm. (C) For the branch counting met
(D) Photomicrographs of laminin expression (green) in control slices and in
bar: 400 μm. The vascular density increased in all conditions compared to c
expressed in % of control. ** p<0.01 (F) Quantification of branching 24 hou
branching are significant at 24 h post seizure,* p<0.05, ** p<0.01.slices (Figure 1B, C). We evaluated the branching and the
vascular density 24 h post-treatment. A significant increase
in vascular density was observed in all conditions indicating
that seizures and also inflammation are sufficient to induce
a vascular remodeling, p<0.01 compared to control
(Figure 1D, E). However laminin staining showed an
increased vascular network in CA1 and CA3 areas after kai-
nate treatment compared to other conditions (Figure 1D).
Neuronal death also occurred in these two areas after kai-
nate treatment [27]. We quantified the branching in CA1c hippocampal culture. (A) Schematic diagram of a blood vessel
od capillary from the existing one. The branch point is essential for the
method, blood vessels are stained with laminin, a specific marker of
f crossings of one vessel on the grid is counted. Therefore, the
ameter of blood vessels. For organotypic cultures, the vascular density
hod, all branch points (circles) are manually counted. Scale bar: 50 μm.
slices 24 h post-treatment with kainate, LPS, bicuculline or VEGF. Scale
ontrol slices. (E) Quantification of vascular density. Results are
rs after seizures induced by kainate or bicuculline. The increases in
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ments. An increase of branching was observed in all condi-
tions. Interestingly the branching was significantly higher in
the case of seizures associated with neuronal death (kai-
nate) than seizures alone (bicuculline), p<0.01 and 0.05, re-
spectively, compared to control (Figure 1F).
We found an increase in vascular density and branch-
ing after in vitro seizures or inflammation, similar to
previous results from rodent models or human tissue
[21,22]. However, depending on the presence or absenceFigure 2 Blood brain barrier integrity in organotypic slices. (A) Schem
endothelial cells joined together by TJ proteins namely ZO-1, claudin-5 and
complex. Occludin and claudin-5 are membrane proteins responsible for ju
membrane proteins and actin. ZO-1 is responsible for the presence of TJ p
of astrocytes and by pericytes, both essential for the maintenance and regu
Many transporters are present at the BBB, including P-glycoprotein (P-gp) a
nutrient passage and brain detoxification, and play an important role in the
(GFAP- green) staining in control slices, or 24 hours after treatment with bi
50 μm. (C) Quantification of western blot for claudin-5, occludin and ZO-1,
percent of control. ** p<0.01 (D) Photomicrographs of ZO-1 (green) and la
kainate in vitro seizures. Scale bar: 10 μm.of neuronal death, the vascular remodeling appeared to
be different with an increase in branching in lesion
areas. In the following study we compared changes in
the NVU between the kainate and bicuculline models.
Roles and modifications of NVU cells in pathological
conditions
The NVU is mainly composed of endothelial cells char-
acterized by limited transport due to the presence of
transporters and TJs. In the brain microvasculature, cellsatic representation of the NVU. Brain vessels are composed of
occludin but also by adherens junctions (AJs) with cadherin/catenin
nction formation and ionic transport. ZO-1 and catenin bind
roteins at the membrane. Endothelial cells are surrounded by end-feet
lation of the NVU. Neurons and microglia are also present in the NVU.
nd Glucose transporter-1 (Glut-1). All transporters are involved in
pharmaco-resistance. (B) Blood vessel (laminin- red) and astrocyte
cuculline or kainate. Arrows represent astrocyte end-feet. Scale bar:
24 hours after bicuculline or kainate seizures. Results are expressed in
minin (red) staining in control slices and 24 h after bicuculline or
Figure 3 Organotypic slices are accessible for molecular screening in culture medium. (A) Membranes representing the cytokine micro-
array performed on culture medium 24 h after LPS, bicuculline or kainate treatment. Control corresponds to the culture medium of organotypic
slices without treatment. (B) Heatmaps representing the optical density for each cytokine. Green represents low expression whereas red
corresponds to high expression.
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cytes. These cells play strategic roles in both formation
and maintenance of the NVU, and also in neurovascular
coupling [1,9,28-30] (Figure 2A). The presence of astro-
cyte end-feet along and surrounding blood vessels was
demonstrated by GFAP staining in control organotypic
cultures (Figure 2B, arrows). The presence of these cells
around blood vessels is modified in pathological conditions.
Indeed, we observed a reduction of astrocyte end-feet 24 h
after kainate treatment. However, after seizures without
lesions, end-feet appeared intact (Figure 2B, arrows).
The main characteristic of the NVU is the presence of TJ
proteins which scaffold the junctions between endothelial
cells. These proteins are essential for a high transendothe-
lial electrical resistance (TEER) (Figure 2A) [29,31]. The
three important TJ proteins, ZO-1, claudin-5 and occludin,
are preserved in culture for several weeks [21,32].
We studied the regulation of ZO-1, claudin-5 and
occludin 24 h post-seizure induced by either kainate or
bicuculline. In the kainate model, Western blot analysis
revealed a significant down-regulation only for ZO-1,
p<0.01. In the bicuculline model the expression of thethree main TJ proteins was not affected (Figure 2C). The
staining of ZO-1 and laminin revealed a regular staining
of the TJ proteins along blood vessels in control slices.
Similar staining was observed 24 h post-bicuculline sei-
zures. However, at 24 h post-kainate seizures, ZO-1
staining was absent along blood vessels (Figure 2D). This
experiment on OHCs showed that NVU remodeling is
dependent on severity of neuronal damage induced by
epileptiform stimuli.
OHCs are accessible for molecule screening in the culture
medium
The tissue or culture medium from OHCs can be ana-
lysed by molecular screening techniques. Due to differ-
ences in branching and the regulation of NVU between
two seizure models, we can expect differences in the se-
cretion and release of angiogenic factors or cytokines.
With a protein array, we evaluated the levels of secreted
cytokines 24 h after seizures induced by kainate or bicu-
culline. As negative and positive controls, we used the
medium of non-treated slices and the medium of OHCs
treated with LPS. In the medium from non-treated slices,
Table 1 Role of cytokines in inflammation, angiogenesis and BBB permeability
Cytokines Others name Inflammation Angiogenesis BBB disruption References
CINC-1 CXCL-1 or Gro-a Pro Pro / [34]
[35]
CINC-2 CXCL-3 or Gro-g Pro Pro / [35]
[36]
CINC-3 CXCL-2 or Gro-B Pro Pro / [35]
[37]
CNTF Pro / / [38]
Fractaline CX3CL-1 Pro Pro / [39]
[40]
GM-CSF Pro Pro Pro [40]
[41]
[42]
S-ICAM-1 CD54 / / /
IFN-g Pro Anti Pro [43]
[41]
[44]
IL1-a Pro Pro Pro [43]
[45]
[46]
IL1-b Pro Pro Pro [45]
[47]
[48]
IL1-ra Anti Anti / [49]
IL-2 Pro Pro Pro [50]
[51]
IL3 Pro / [52]
IL4 Pro Anti Pro [50]
[51]
[35]
IL6 Pro and anti Pro Pro [35]
[48]
[53]
IL10 Anti Anti / [54]
IP-10 CXCL10 Pro Anti / [35]
LIX CXCL5 Pro Pro / [35]
L-selectine CD62L / / /
MIG CXCL9 Pro Anti / [35]
MIP-1a CCL3 Pro / / [35]
MIP-3a CCL20 Pro / / [55]
RANTES CCL5 Pro Anti Pro [56]
TIMP-1 / Anti / [57]
TNF-a Pro Pro Pro [48]
[35]
VEGF / Pro Pro [58]
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Figure 4 Organotypic slices are accessible for analysis of proteins in tissue. (A) Analysis of VEGF expression by Western blot 2, 12 and 24 h
post-bicuculline treatment. Results are expressed in percent of control, * p<0.05. (B) Immunostaining of VEGF (green), NeuN or laminin (red) and
GFAP (blue) in control slices or 12 h post-bicuculline seizures (PS). VEGF is expressed in neurons and in astrocytes around blood vessels (arrows),
Scale bar 10 μm. (C) Analysis of VEGFR-2 expression and activation by Western blot 2, 12 and 24 h post-bicuculline treatment. Results are
expressed in percent of control, * p<0.05. (D) Immunostaining of VEGFR-2 (green), NeuN or laminin (red) in control slices or 12 h post-bicuculline
seizures. VEGFR-2 is expressed in neurons and along blood vessels 12 h after bicuculline treatment. Scale bar 10 μm. (E) Analysis of Ang1 and
Ang2 expression by Western blot 24 h post-bicuculline or kainate treatment. Results are expressed in percent of control, * p<0.05, ** p<0.01.
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inhibitor-1 (TIMP)-1 while 24 h after LPS treatment,
many additional cytokines were secreted into the culture
medium. After seizure induction, we observed different
patterns between kainate and bicuculline models. In kai-
nate model, cytokines present in the culture medium indi-
cated an inflammatory process, confirming previous
results [27,33]. In contrast, 24 h after bicuculline seizures,
cytokine patterns were identical to those in control slices
(Figure 3A). These differences in cytokine profiles were
confirmed by heatmap analysis. We focused in more detail
on cytokines known to be involved in vascular remodeling
by inducing angiogenesis or increased BBB permeability.VEGF, IL-1β, IL-1α, IL-6, IL-13 and also TNF-α are pro-
angiogenic, while IFN-γ, IL-1β and VEGF can also par-
ticipate in BBB permeability (Table 1). Most of these
cytokines, including IL-1α, IL1-β but also VEGF, are
present at higher levels in the kainate compared to bicu-
culline model (Figure 3B).
Protein analysis in tissue
Angiogenesis and BBB permeability are hallmarks of
VEGF/VEGFR-2 activation [59]. Their overexpression in
the epileptic focus after experimental seizures suggests that
the VEGF/VEGFR-2 system is a logical new target for
refractory epilepsies [21,22,60,61]. In the kainate model, we
Figure 5 Organotypic slices are accessible for drugs testing. (A) Immunostaining of ZO-1 (green) and laminin (red) in control slices and 24 h
post-kainate seizures with or without rh-Ang1 application 4 h post-seizures. Rh-Ang-1 repaired the loss of ZO-1 (green) in blood vessels (laminin,
red). Scale bar: 50 μm (B) Analysis of Zonula occludens-1 expression by Western blot 24 h post-kainate treatment with or without rhAng1
application. Results are expressed in percent of control, * p<0.05.
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VEGFR-2 signaling, leading to the downregulation of ZO-1
[21]. The lower level of VEGF in the culture medium of
OHCs after bicuculline treatment suggested a different
regulation of angiogenic factors that does not trigger a loss
of TJ proteins.
Western blotting and immunostaining demonstrated
an overexpression of VEGF only 12 h after bicuculline
application, p<0.05 (Figure 4A). Increased VEGF was
observed in astrocytic end-feet and surrounding blood
vessels (arrows, Figure 4B). We next studied the expres-
sion and activation of VEGFR-2. An increase in VEGFR-2
expression was also detected 12 h post-seizure, p<0.05.
However, the activation of VEGFR-2, measured by the
phosphorylation of the receptor, was visible at 2 and 12 h
post-seizure, p<0.05 for both (Figure 4C). The immunos-
taining revealed an overexpression of the receptor in neu-
rons but more particularly in blood vessels (Figure 4D).After bicuculline-induced seizures, we observed a similar
upregulation of the VEGF/VEGFR-2 system.
To understand differences in the regulation of tight
junctions between the two seizure models, we focused
on the angiopoietin system, composed of angiopoietin-1
and 2 (Ang1 and Ang2). These two proteins have oppos-
ite effects on the BBB integrity; Ang1 is involved in the
maturation of blood vessels and participates in the BBB
integrity, whereas Ang2 appears in early stages of the
angiogenesis and disrupts the BBB [62-65]. We decided
to study the regulation of these two proteins 24 h after ei-
ther kainate or bicuculline seizures, a time-point where
ZO-1 is downregulated in the kainate model only. By
Western blotting, we observed the same level of Ang1 as
in control slices but a significant downregulation of Ang2
following bicuculline seizures, p<0.01. However, after kai-
nate seizures, Ang1 expression was significantly lower
than in control slices, p<0.05, whereas Ang2 was
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suggest that angiopoietin system could play an important
role in the regulation of TJ proteins after epileptic
seizures.
Drug testing and molecular screening
Due to their easy accessibility, OHCs are excellent tools
for pharmacological and biochemical assays, including
drug screening for BBB protective compounds that
could improve the treatments for ischemic or traumatic
injuries [66,67]. We have already demonstrated the use of
neutralizing antibodies in OHCs. We neutralized VEGF
with an anti-VEGF antibody (bevacizumab) that prevents
VEGF binding to its receptor. Despite the thickness of the
culture plus insert at around 150 μm, the addition of this
neutralizing antibody abolished both the down-regulation
of ZO-1 protein and increased vascularisation induced by
in vitro seizures [21]. Since in this study a deregulation of
the Ang proteins was observed only in the model where
ZO-1 was also downregulated, we tested the effect of re-
combinant Angiopoietin-1 (rhAng-1) applied to the cul-
ture medium. To determine if we can restore ZO-1
expression after kainate seizures, rhAng1 was added to the
culture medium 4 h post-seizures. In control slices treated
with rhAng1, the staining pattern of ZO-1 along blood
vessels did not change compared to control slices. Treat-
ment with rhAng1 after kainate seizures restored the pres-
ence of ZO-1 protein (Figure 5A). Western blot analysis
confirmed the above results, showing a significant increase
of ZO-1 expression after rhAng1 addition, p<0.05, and
confirming that Ang1 plays an important role in the res-
toration of BBB integrity (Figure 5B).
Discussion
Due to the presence of all cell types and their interactions,
preservation of TJs between endothelial cells, as well as
BBB carriers and transporters, brain slices provide a
complete ex vivo model of the NVU, although in the ab-
sence of blood flow. For example, we have observed that
NVU alterations in OHSc, including increased vascularisa-
tion and TJ disassembly, were similar to those reported in
human in vivo focal epilepsy. Other cell types present at
the BBB can be studied in OHCs. Indeed, a recent paper
focused on the intact functions of NVU in OHCs, showing
that calcium signaling can be investigated in astrocyte
end-feet and that the contractile properties of pericytes,
necessary for vasomodulation, are conserved for weeks in
culture [11,68]. Moreover, microglia and neurons are also
present in the NVU, but the role of microglia in NVU
regulation is still not clear and poorly studied in organoty-
pic cultures. The only link between microglia and blood
vessels was the presence of active microglia surrounding
blood vessels in retinal organotypic cultures [69]. Finally,
the presence of transporters such as glucose transporter−1and P-glycoprotein on brain endothelial cells in organoty-
pic slices has been previously documented. Moreover, it
has been shown that the transport function of P-gp,
involved in the pharmacoresistance of several neurological
diseases, is still preserved in organotypic slices [30].
Organotypic slices are also useful for testing the ability
of different drugs to affect/protect the NVU, such as inhi-
bitors of signaling pathways and neutralizing antibodies
[21]. In this study we showed that NVU integrity was
restored by the application of recombinant Ang1. BBB
dysfunction in diverse CNS disorders, including epilepsy,
Alzheimer’s disease and ischemia, is in part due to the loss
of AJ or TJ proteins along microvessels [21,22,70,71].
However, a limitation of organotypic cultures is the lack
of tools to estimate BBB permeability, which is altered in
several brain pathologies [22,72-74]. Staining for serum
protein leakage or the measurement of TEER in vitro [75]
is not possible in this model. To counteract this issue, a
co-culture model of endothelial cells and brain slices has
been developed in which Duport and colleagues showed
that the BBB permeability can be evaluated by microdialy-
sis [76].
In the past decade, alterations in the neuro-vasculature
have been shown to be important in many CNS diseases,
including glioma, stroke, Alzheimer’s disease and epilepsy
[2-5,77]. However the mechanisms of NVU dysregulation
are still unknown in several pathologies. Using organoty-
pic slice cultures to study NVU embedded in the micro-
environment of anatomically organized parenchymal cells
and maintaining many important physiological functions,
will undoubtedly facilitate future studies on mechanisms
and impact of pathological conditions on NVU remodel-
ing as well as its role in disease processes.
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